Anti-PD-1/PD-L1免疫檢查點抑制劑的皮膚副作用

10.6666/ClinMed.202102_87(2).0019

張綜顯；張雲亭

抗細胞程式死亡受體-1（anti-programmed cell death protein-1, anti-PD-1） ； 抗細胞程式死亡配體-1（anti-programmed cell death ligand-1, anti-PD-L1） ； 免疫檢查點抑制劑（immune checkpoint inhibitor） ； 免疫相關不良反應（immune-related adverse event, irAE）

臨床醫學月刊

87卷2期（2021 / 02 / 26）

123 - 126

繁體中文

免疫檢查點抑制劑（immune checkpoint inhibitors）是近幾年來癌症治療的重大突破，其中anti-PD-1（anti-programmed cell death protein-1）與anti-PD-L1（anti-programmed cell death ligand-1）已成為許多癌症末期時的第一線治療藥物。然而，在達到療效的同時，這些藥物藥物也會引發免疫相關不良反應（immune-related adverse event, irAE），其中皮膚即為最容易發生irAE的器官。能早期識別並即時治療皮膚irAE十分重要，因其可遏止皮膚症狀惡化，並避免因延緩或終止anti-PD-1/PD-L1治療導致癌症進展。

1. Freeman-Keller, M,Kim, Y,Cronin, H(2016).Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.Clin Cancer Res,22,886-894.
2. Griffin, LL,Cove-Smith, L,Alachkar, H(2018).Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma.JAAD Case Rep,4,229-231.
3. Hua, C,Boussemart, L,Mateus, C(2016).Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.JAMA Dermatol,152,45-51.
4. Naidoo, J,Page, DB,Li, BT(2015).Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.Ann Oncol,26,2375-2391.
5. Robert, C,Long, GV,Brady, B(2015).Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med,372,320-330.
6. Robert, C,Schachter, J,Long, GV(2015).Pembrolizumab versus Ipilimumab in Advanced Melanoma.N Engl J Med,372,2521-2532.
7. Sanlorenzo, M,Vujic, I,Daud, A(2015).Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.JAMA Dermatol,151,1206-1212.
8. Saw, S,Lee, HY,Ng, QS(2017).Pembrolizumab-induced Stevens–Johnson syndrome in non-melanoma patients.European Journal of Cancer,81,237-239.
9. Schaberg, KB,Novoa, RA,Wakelee, HA(2016).Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.J Cutan Pathol,43,339-346.
10. Shi, VJ,Rodic, N,Gettinger, S(2016).Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy.JAMA Dermatol,152,1128-1136.
11. Sibaud, V,Meyer, N,Lamant, L(2016).Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.Current Opinion in Oncology,28,254-263.
12. Voudouri, D,Nikolaou, V,Laschos, K(2017).Anti-PD1/PDL1 induced psoriasis.Curr Probl Cancer,41,407-412.